References
- Milovanovic M, Volarevic V, Radosavljevic G, et al. IL-33/ST2 axis in inflammation and immunopathology. Immunol Res. 2012;52(1–2):89–99
- Miller AM. Role of IL-33 in inflammation and disease. J Inflamm (Lond). 2011;8(1):22
- Moussion C, Ortega N, Girard JP. The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel “alarmin”? PloS One. 2008;3(10):e3331
- Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31(1):5–7
- Akcay A, Nguyen Q, He Z, et al. IL-33 exacerbates acute kidney injury. JASN. 2011;22(11):2057–2067
- Satirapoj B. Nephropathy in diabetes. Adv Exp Med Biol. 2012;771:107–122
- Satirapoj B. Review on pathophysiology and treatment of diabetic kidney disease. J Med Assoc Thai. 2010;93(Suppl 6):S228–S241
- McKenna K, Thompson C. Microalbuminuria: a marker to increased renal and cardiovascular risk in diabetes mellitus. Scot Med J. 1997;42(4):99–104
- Arababadi MK, Pourfathollah AA, Daneshmandi S, et al. Evaluation of relation between IL-4 and IFN-g polymorphisms and type 2 diabetes. IJBMS. 2009;12(2):100–104
- Miller AM, Purves D, McConnachie A, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PloS One. 2012;7(10):e47830
- Bao YS, Na SP, Zhang P, et al. Characterization of interleukin-33 and soluble ST2 in serum and their association with disease severity in patients with chronic kidney disease. J Clin Immunol. 2012;32(3):587–594
- Musolino C, Allegra A, Profita M, et al. Reduced IL-33 plasma levels in multiple myeloma patients are associated with more advanced stage of disease. Brit J Haematol. 2013;160(5):709–710